TY - JOUR
T1 - Emergence of Low-level Delamanid and Bedaquiline Resistance during Extremely Drug-resistant Tuberculosis Treatment
AU - Polsfuss, Silke
AU - Hofmann-Thiel, Sabine
AU - Merker, Matthias
AU - Krieger, David
AU - Niemann, Stefan
AU - Rüssmann, Holger
AU - Schönfeld, Nicolas
AU - Hoffmann, Harald
AU - Kranzer, Katharina
N1 - Publisher Copyright:
© 2019 The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/9/13
Y1 - 2019/9/13
N2 - Two new drugs, delamanid and bedaquiline, have recently been approved for treatment of multidrug-resistant and extensively drug-resistant (XDR) tuberculosis. Here, we report a case of clofazimine, bedaquiline, and low-level delamanid resistances acquired during treatment of a patient with XDR tuberculosis.
AB - Two new drugs, delamanid and bedaquiline, have recently been approved for treatment of multidrug-resistant and extensively drug-resistant (XDR) tuberculosis. Here, we report a case of clofazimine, bedaquiline, and low-level delamanid resistances acquired during treatment of a patient with XDR tuberculosis.
UR - http://www.scopus.com/inward/record.url?scp=85065770908&partnerID=8YFLogxK
U2 - 10.1093/cid/ciz074
DO - 10.1093/cid/ciz074
M3 - Journal articles
C2 - 30933266
AN - SCOPUS:85065770908
SN - 1058-4838
VL - 69
SP - 1229
EP - 1231
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 7
ER -
